ArticleCureus2026
Diffuse Alveolar Hemorrhage Mimicking Pneumonia in a Patient With Interstitial Lung Disease on Ticagrelor.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diffuse alveolar hemorrhage (DAH) is a rare and potentially life-threatening cause of acute hypoxemic respiratory failure and may be difficult to diagnose in patients with underlying interstitial lung disease (ILD). Ticagrelor frequently causes dyspnea, but DAH related to its use is exceedingly uncommon. We report the case of a 74-year-old man with chronic ILD and recent percutaneous coronary intervention who presented with progressive dyspnea, hypoxemia, and diffuse bilateral ground-glass opacities while receiving dual antiplatelet therapy with ticagrelor. Initial evaluation favored infection or ILD progression. Bronchoscopy with bronchoalveolar lavage demonstrated progressively bloody aliquots, establishing the diagnosis of DAH. Infectious, autoimmune, and thromboembolic causes were excluded, and the temporal relationship to ticagrelor supported a drug-induced etiology. This case highlights the diagnostic challenge of DAH in ILD patients and emphasizes the need for early consideration of medication-related hemorrhage in patients receiving ticagrelor who develop unexplained hypoxemia or hemoptysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.